Tutte le immagini(1)

Key Documents

CdO/CdA

Altri documenti

Y0001079

Benserazide for peak identification

Name: Benserazide for peak identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Benserazide hydrochloride, DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide hydrochloride

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):

C₁₀H₁₅N₃O₅ · HCl

Numero CAS:

14919-77-8

Peso molecolare:

293.70

Numero MDL:

MFCD00078571

Codice UNSPSC:

41116107

ID PubChem:

329831250

NACRES:

NA.24

Prodotti consigliati

Slide 1 of 7

1 of 7

Y0000073

Cetyl palmitate 15

Y0000074

Cetyl palmitate 95

BP968

Benserazide impurity A

Sigma-Aldrich

402788

Acetaldeide

USP

1437009

Metilprednisolone emisuccinato

USP

1535755

Fosfatidilcolina (soia)

Supelco

PHR2107

Acetaldeide

Grado

pharmaceutical primary standard

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

Cl.NC(CO)C(=O)NNCc1ccc(O)c(O)c1O

InChI

1S/C10H15N3O5.ClH/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16;/h1-2,6,12,14-17H,3-4,11H2,(H,13,18);1H
ULFCBIUXQQYDEI-UHFFFAOYSA-N

Informazioni sul gene

human ... DDC(1644)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Benserazide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Inhibitor of L-aromatic amino acid decarboxylase.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.

Wai Kin D Ko et al.

Neurobiology of disease, 70, 138-148 (2014-06-28)

Regulators of G-protein signalling (RGS) proteins are implicated in striatal G-protein coupled receptor (GPCR) sensitisation in the pathophysiology of l-DOPA-induced abnormal involuntary movements (AIMs), also known as dyskinesia (LID), in Parkinson's disease (PD). In this study, we investigated RGS protein

Spinal cord injury enables aromatic L-amino acid decarboxylase cells to synthesize monoamines.

Jacob Wienecke et al.

The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(36), 11984-12000 (2014-09-05)

Serotonin (5-HT), an important modulator of both sensory and motor functions in the mammalian spinal cord, originates mainly in the raphe nuclei of the brainstem. However, following complete transection of the spinal cord, small amounts of 5-HT remain detectable below

Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats.

Sylvia Navailles et al.

CNS neuroscience & therapeutics, 20(7), 671-678 (2014-04-30)

Serotonin (5-HT) neurons mediate the ectopic release of dopamine (DA) induced by L-DOPA in the Parkinsonian brain. We hypothesized that the participation of noradrenalin transporters (NET) in the clearance of DA may account for the lower effect of L-DOPA in

Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.

Dalila Mango et al.

Experimental neurology, 261, 733-743 (2014-09-01)

γ-Aminobutyric acid A receptor (GABAAR)-mediated postsynaptic currents were recorded in brain slices from substantia nigra pars reticulate neurons. The selective adenosine A1 receptor (A1R) antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), increased the frequency, but not the amplitude of spontaneous inhibitory post-synaptic currents (IPSCs)

Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.

Yong Wang et al.

Synapse (New York, N.Y.), 68(8), 332-343 (2014-03-07)

l-3,4-Dihydroxyphenylalanine (L-DOPA) is the most widely used drug for the treatment of Parkinson's disease. Unfortunately, chronic administration of this dopamine precursor causes L-DOPA-induced dyskinesia (LID), which is a debilitating complication whose pathogenesis remains unclear. In this study, we compared gene

Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.